Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843193 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
A Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
- 20
- Study locations
NCT00843193: Completed Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
NCT00843193 is a Phase 2 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 198 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00843193, a Phase 2 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
- 20
- Study locations
Study Summary
Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
Primary Outcome
The ACQ-7 consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). The values of Week 1 is considered as Baseline. ACQ-7 was calculated as the average of the 7 scores. If any one individual score was missing, the ACQ-7 was set to missing.The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value was missing, the change from Baseline
Conditions Studied
Interventions
- DRUG INTRAVENOUS GSK679586
- DRUG INTRAVENOUS PLACEBO
- DRUG FLUTICASONE PROPIONATE
Study Locations (20)
Other
- GSK Investigational Site - Lille
- GSK Investigational Site - Marseille
- GSK Investigational Site - Montpellier
- GSK Investigational Site - Nantes
- GSK Investigational Site - Saint-Pierre
- GSK Investigational Site - Strasbourg
- GSK Investigational Site - Tarbes
- GSK Investigational Site - Eindhoven
- GSK Investigational Site - Heerlen
- GSK Investigational Site - Hoorn
- GSK Investigational Site - Elverum
Oregon
- GSK Investigational Site - Medford
- GSK Investigational Site - Portland
Hesse
- GSK Investigational Site - Frankfurt am Main
- GSK Investigational Site - Gelnhausen
Pennsylvania
- GSK Investigational Site - Pittsburgh
South Carolina
- GSK Investigational Site - Orangeburg
Texas
- GSK Investigational Site - Boerne
Wisconsin
- GSK Investigational Site - Madison
Saxony-Anhalt
- GSK Investigational Site - Magdeburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-12-09 |
| Est. Completion | 2010-07-25 |
| Phase | Phase 2 |
What the finished NCT00843193 record still lists
NCT00843193 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which INTRAVENOUS GSK679586 is the first listed.
NCT00843193 names 20 study sites across 8 states, led by Other, Oregon, Hesse.
Frequently Asked Questions
What is clinical trial NCT00843193 about?
NCT00843193 is a clinical study titled "Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma". Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
What is the current status of trial NCT00843193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2008-12-09. Estimated completion is 2010-07-25.
What conditions does trial NCT00843193 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00843193?
The interventions under investigation include: INTRAVENOUS GSK679586 (DRUG), INTRAVENOUS PLACEBO (DRUG), FLUTICASONE PROPIONATE (DRUG).
Who is sponsoring clinical trial NCT00843193?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00843193 being conducted?
This trial has 20 study locations across Oregon, Pennsylvania, South Carolina, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00843193's enrollment target sits among peer trials
198 166th of 374 higher than 208 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI